MISSY EDWARDS STRATEGIES, LLC for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Following issues related to the budget and appropriations process FY13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA M EDWARDS | Legislative Assistant to Senator Thad Cochran |
Taxation/Internal Revenue Code TAX
General tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned U.S. corporations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA M EDWARDS New | Legislative Assistant to Senator Thad Cochran |
Health Issues HCR
Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; issues relating to PDUFA stimulus. Legislation on public health preparedness and response related to pandemic influenza. Avastin-use in breast cancer treatment; general patent reform issues; implementation of the Affordable Care Act of 2010
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA M EDWARDS | Legislative Assistant to Senator Thad Cochran |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| F. HOFFMANN-LA ROCHE LTD. | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.